Pricing Agreement

Goldman, Sachs & Co.

200 West Street

New York, New York 10282

J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

One Bryant Park

New York, New York 10036

Morgan Stanley & Co. LLC

1585 Broadway

New York, New York 10036

As Representatives of the several Underwriters

named in Schedule I hereto

Ladies and Gentlemen:

UnitedHealth Group Incorporated, a Minnesota corporation (the “Company”), proposes, subject to the terms and conditions stated herein (the “Pricing Agreement”) and in the underwriting agreement, dated December 3, 2014 (the “Agreement”), between the Company on the one hand and Goldman, Sachs & Co., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC, as representatives (the “Representatives”) of the several underwriters named in Schedule I hereto (the “Underwriters”), on the other hand, to issue and sell to the Underwriters the Securities specified in Schedule II hereto (the “Designated Securities”). Each of the provisions of the Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Pricing Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Pricing Agreement, except that each representation and warranty which refers to the Prospectus in Section 3 of the Agreement shall be deemed to be a representation or warranty as of the date of the Agreement in relation to the Prospectus (as therein defined), and also a representation and warranty as of the date of this Pricing Agreement in relation to the Prospectus as amended or supplemented relating to the Designated Securities which are the subject of this Pricing Agreement. Unless otherwise defined herein, terms defined in the Agreement are used herein as therein defined. The Representatives designated to act on behalf of the Representatives and on behalf of each of the Underwriters of the Designated Securities pursuant to Section 15 of the Agreement and the addresses of the Representatives referred to in such Section 15 are set forth at the end of Schedule II hereto.

An amendment to the Registration Statement, or a supplement to the Prospectus, as the case may be, relating to the Designated Securities, in the form heretofore delivered to you is now proposed to be filed with the Commission.

At or prior to 4:15 p.m. (Eastern Time) on December 3, 2014 (the “Time of Sale”), the Company had prepared the following information (collectively, the “Time of Sale Information”): the Preliminary Prospectus dated December 3, 2014 (including the Base Prospectus dated February 14, 2014), and the “free writing prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Schedule III hereto, including a final term sheet in the form set forth in Schedule IV hereto.

Subject to the terms and conditions set forth herein and in the Agreement incorporated herein by reference, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the time and place and at the purchase price to the Underwriters set forth in Schedule II hereto, the principal amount of Designated Securities set forth opposite the name of such Underwriter in Schedule I hereto.

If the foregoing is in accordance with your understanding, please sign and return to us five counterparts hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof, including the provisions of the Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is or will be pursuant to the authority set forth in a form of Agreement among Underwriters or power of attorney, the form or forms of which shall be submitted to the Company for examination upon request.

Very truly yours,

By: GOLDMAN, SACHS & CO.

By:    /s/ Adam Greene    

Name:    Adam Green

Title:    Vice President

By: J.P. MORGAN SECURITIES LLC    

By:    /s/ Robert Bottamedi    

Name:    Robert Bottamedi

Title:    Vice President

By: MERRILL LYNCH, PIERCE, FENNER & SMITH

INCORPORATED

By:    /s/ Douglas Muller    

Name:    Douglas Muller

Title:    Managing Director

By: MORGAN STANLEY & CO. LLC    

By:    /s/ Yurij Slyz    

Name:    Yurij Slyz

Title:    Executive Director

As Representatives of the several Underwriters

named in Schedule I hereto

1.400% Notes Due December 15, 2017 (the “2017 Notes”)

2.300% Notes Due December 15, 2019 (the “2019 Notes”)

2.875% Notes Due December 15, 2021 (the “2021 Notes”)

$750,000,000 for the 2017 Notes

$500,000,000 for the 2019 Notes

$750,000,000 for the 2021 Notes

2017 Notes: 99.862% of the principal amount of the 2017 Notes, plus accrued interest, if any, from December 8, 2014.

2019 Notes: 99.821% of the principal amount of the 2019 Notes, plus accrued interest, if any, from December 8, 2014.

2021 Notes: 99.892% of the principal amount of the 2021 Notes, plus accrued interest, if any, from December 8, 2014.

2017 Notes: 99.612% of the principal amount of the 2017 Notes, plus accrued interest, if any, from December 8, 2014, if settlement occurs after that date.

2019 Notes: 99.471% of the principal amount of the 2019 Notes, plus accrued interest, if any, from December 8, 2014, if settlement occurs after that date.

2021 Notes: 99.492% of the principal amount of the 2021 Notes, plus accrued interest, if any, from December 8, 2014, if settlement occurs after that date.

Book-entry only form represented by one or more global securities deposited with The Depository Trust Company (“DTC”) or its designated custodian, to be made available for checking by the Representatives at least twenty-four hours prior to the Time of Delivery at the office of DTC.

Federal (same-day) funds

9:00 a.m. (New York City time), December 8, 2014

Indenture, dated as of February 4, 2008, between the Company and U.S. Bank National Association, as Trustee.

2017 Notes: December 15, 2017

2019 Notes: December 15, 2019

2021 Notes: December 15, 2021

2017 Notes: 1.400%

2019 Notes: 2.300%

2021 Notes: 2.875%

2017 Notes: June 15 and December 15, commencing June 15, 2015.

2019 Notes: June 15 and December 15, commencing June 15, 2015.

2021 Notes: June 15 and December 15, commencing June 15, 2015.

The 2017 Notes, the 2019 Notes and the 2021 Notes are redeemable by the Company, in whole or in part and at any time on not less than 30 nor more than 60 days’ notice by mail, at the applicable redemption prices described in the Prospectus under the heading “Description of the Notes-Optional Redemption.”

Upon the occurrence of a Change of Control Triggering Event (as defined in the Prospectus), the Company will be required to make an offer to repurchase the Notes at a price equal to 101% of the principal amount of the Notes, plus accrued and unpaid interest to, but not including, the date of repurchase.

No sinking fund provisions.

Defeasance provisions set forth in Article IX of the Indenture shall apply to the Designated Securities.

December 8, 2014, at 9:00 a.m. (New York City time) at the offices of Simpson Thacher & Bartlett LLP, 425 Lexington Avenue, New York, New York 10017.

As to the 2017 Notes, the 2019 Notes and the 2021 Notes (and designated to act on behalf of the other Underwriters or other Representatives):

Goldman, Sachs & Co.

200 West Street

New York, New York 10282

Attention: Prospectus Department

J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

Attention: Investment Grade Syndicate Desk - 3rd floor

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

One Bryant Park

New York, New York 10036

Attention: High Grade Debt Capital Markets Transaction Management/Legal

Morgan Stanley & Co. LLC

1585 Broadway

New York, New York 10036

Attention: Investment Banking Division

*Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision, suspension or withdrawal at any time.